Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 10:51 PM
Ignite Modification Date: 2025-12-25 @ 8:20 PM
NCT ID: NCT05119569
Description: Safety population included all participants who received any study drug. Data collected up to the primary completion date is reported here. Adverse events section will be updated one year after the study completion date.
Frequency Threshold: 5
Time Frame: Up to Week 12
Study: NCT05119569
Study Brief: A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
DBT Phase: Fenebrutinib Participants received fenebrutinib, 200 mg, orally, BID for 12 weeks during the DBT phase. 0 None 0 73 8 73 View
DBT Phase: Placebo Participants received fenebrutinib matching placebo, orally, BID for 12 weeks during the DBT phase. 0 None 0 36 4 36 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Urinary tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 26.0 View
Hepatic enzyme abnormal SYSTEMATIC_ASSESSMENT Investigations MedDRA 26.0 View
Hypertension SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA 26.0 View